Evidence map›Paper›PMID 34803447›Full record

ArticleTurkish journal of biology = Turk biyoloji dergisi2021

Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease.

Lalehan Oktay, Ece Erdemoğlu, İlayda Tolu, Yeşim Yumak, Ayşenur Özcan, Elif Acar, Şehriban Büyükkiliç, Alpsu Olkan, Serdar Durdaği

Abstract read
In one paragraph

Article in Turkish journal of biology = Turk biyoloji dergisi, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lalehan OktayComputational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahçeşehir University, İstanbul Turkey.ORCID https://orcid.org/0000-0002-3293-5551
Ece ErdemoğluComputational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahçeşehir University, İstanbul Turkey.ORCID https://orcid.org/0000-0002-6084-2037
İlayda ToluComputational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahçeşehir University, İstanbul Turkey.ORCID https://orcid.org/0000-0002-0106-5426
Yeşim YumakComputational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahçeşehir University, İstanbul Turkey.ORCID https://orcid.org/0000-0001-5227-0932
Ayşenur ÖzcanComputational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahçeşehir University, İstanbul Turkey.ORCID https://orcid.org/0000-0002-8493-7380
Elif AcarComputational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahçeşehir University, İstanbul Turkey.ORCID https://orcid.org/0000-0002-8180-227X
Şehriban BüyükkiliçComputational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahçeşehir University, İstanbul Turkey.ORCID https://orcid.org/0000-0003-2390-3379
Alpsu OlkanComputational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahçeşehir University, İstanbul Turkey.ORCID https://orcid.org/0000-0002-8938-6952
Serdar DurdağiComputational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahçeşehir University, İstanbul Turkey.ORCID https://orcid.org/0000-0002-0426-0905

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the emergence of the new SARS-CoV-2 virus, drug repurposing studies have gained substantial importance. Combined with the efficacy of recent improvements in ligand- and target-based virtual screening approaches, virtual screening has become faster and more productive than ever. In the current study, an FDA library of approved drugs and compounds under clinical investigation were screened for their antiviral activity using the antiviral therapeutic activity binary QSAR model of the MetaCore/MetaDrug platform. Among 6733-compound collection, we found 370 compounds with a normalized therapeutic activity value greater than a cutoff of 0.75. Only these selected compounds were used for molecular docking studies against the SARS-CoV-2 main protease (M

Indexed as

Binary QSARdrug repurposingSARS-CoV-2virtual screening

Identifiers

PMID34803447
PMCPMC8573836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.